華寶股份(300741.SZ):鷹潭華寶、雲南天宏再次獲得高新技術企業證書
格隆匯2月23日丨華寶股份(300741.SZ)公佈,公司下屬全資子公司鷹潭華寶香精有限公司(“鷹潭華寶”)、控股子公司雲南天宏香精有限公司(“雲南天宏”)近日分別收到《高新技術企業證書》。
根據《中華人民共和國企業所得税法》以及國家對高新技術企業的相關税收規定,鷹潭華寶、雲南天宏自本次被重新認定為高新技術企業後連續三年內可繼續享受國家關於高新技術企業的相關優惠政策,按應納税所得額15%的税率繳納企業所得税。鷹潭華寶、雲南天宏曾於2018年通過高新技術企業認定,有效期為三年,本次高新技術企業的認定系原證書有效期滿後所進行的重新認定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.